Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma - PubMed (original) (raw)

Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma

Liqiang Qi et al. BMC Cancer. 2009.

Abstract

Background: Flat epithelial atypia (FEA) of the breast is characterised by a few layers of mildly atypical luminal epithelial cells. Genetic changes found in ductal carcinoma in situ (DCIS) and invasive ductal breast cancer (IDC) are also found in FEA, albeit at a lower concentration. So far, miRNA expression changes associated with invasive breast cancer, like miR-21, have not been studied in FEA.

Methods: We performed miRNA in-situ hybridization (ISH) on 15 cases with simultaneous presence of normal breast tissue, FEA and/or DCIS and 17 additional cases with IDC. Expression of the miR-21 targets PDCD4, TM1 and PTEN was investigated by immunohistochemistry.

Results: Two out of fifteen cases showed positive staining for miR-21 in normal breast ductal epithelium, seven out of fifteen cases were positive in the FEA component and nine out of twelve cases were positive in the DCIS component. A positive staining of miR-21 was observed in 15 of 17 IDC cases. In 12 cases all three components were present in one tissue block and an increase of miR-21 from normal breast to FEA and to DCIS was observed in five cases. In three cases the FEA component was negative, whereas the DCIS component was positive for miR-21. In three other cases, normal, FEA and DCIS components were negative for miR-21 and in the last case all three components were positive. Overall we observed a gradual increase in percentage of miR-21 positive cases from normal, to FEA, DCIS and IDC. Immunohistochemical staining for PTEN revealed no obvious changes in staining intensities in normal, FEA, DCIS and IDC. Cytoplasmic staining of PDCD4 increased from normal to IDC, whereas, the nuclear staining decreased. TM1 staining decreased from positive in normal breast to negative in most DCIS and IDC cases. In FEA, the staining pattern for TM1 was similar to normal breast tissue.

Conclusion: Upregulation of miR-21 from normal ductal epithelial cells of the breast to FEA, DCIS and IDC parallels morphologically defined carcinogenesis. No clear relation was observed between the staining pattern of miR-21 and its previously reported target genes.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Expression of miR-21 in 5 patients presenting simultaneously with normal breast epithelium, FEA, DCIS by RNA ISH. The expression of miR-21 was detected predominantly in the cytoplasm in luminal cells. An increase in staining intensity for miR-21 was observed from normal, to FEA and DCIS in these 5 patients. Staining intensity in FEA and DCIS was similar in 4 out of 5 cases (200×).

Figure 2

Figure 2

Expression of miR-21 in IDC by RNA ISH. A representative example of IDC showing strong cytoplasmic staining in the vast majority of the tumor cells.(200×).

Figure 3

Figure 3

Staining of three predicted miR-21 target genes in normal, FEA, DCIS and IDC tissue. PTEN showed nuclear staining and was expressed strongly in normal, FEA, DCIS and IDC. TM1 expression in normal, FEA, DCIS and IDC showed cytoplasmic staining and there was a decrease from normal to FEA, DCIS and IDC. PDCD4 was expressed mainly in nuclei in normal breast while the staining pattern gradually shifted from nuclear to cytoplasmic in FEA, DCIS and IDC (400× magnification for all).

Similar articles

Cited by

References

    1. Tavassoli FADP. World Health Organization classification of tumors of pathology and genetics, tumors of the breast and female genital organs. Lyon: IARC Press; 2003.
    1. Schnitt SJ. The diagnosis and management of pre-invasive breast disease: flat epithelial atypia – classification, pathologic features and clinical significance. Breast Cancer Res. 2003;5:263–268. doi: 10.1186/bcr625. - DOI - PMC - PubMed
    1. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11:223–235. - PubMed
    1. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001;19:2263–2271. - PubMed
    1. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium. Cancer. 2000;88:2072–2081. doi: 10.1002/(SICI)1097-0142(20000501)88:9<2072::AID-CNCR13>3.0.CO;2-H. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources